NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

非侵入性癌症診斷的全球市場(2021年∼2028年)

Global Noninvasive Cancer Diagnostics Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1008248
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
非侵入性癌症診斷的全球市場(2021年∼2028年) Global Noninvasive Cancer Diagnostics Market - 2021-2028
出版日期: 2021年05月27日內容資訊: 英文 180 Pages
簡介

非侵入性癌症診斷市場受到多種因素的推動,例如各種類型癌症(包括乳腺癌和肺癌等慢性癌症)的患病率不斷增加,以及人口老齡化加劇。在早期發現癌症大大增加了生存機會。促進早期診斷的提高認識活動和篩查對於早期發現癌症是必不可少的。然而,診斷程序的高成本和嚴格的監管要求正在阻礙全球市場的增長。

本報告提供全球非侵入性癌症診斷市場的相關調查,提供市場機會和影響,成長及阻礙因素,療法·技術·終端用戶·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 全球非侵入性癌症診斷市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球非侵入性癌症診斷市場-市場定義和概要

第3章 全球非侵入性癌症診斷市場-摘要整理

  • 各療法市場明細
  • 各技術市場明細
  • 各終端用戶市場明細
  • 各地區的市場明細

第4章 全球非侵入性癌症診斷市場-市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球非侵入性癌症診斷市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球非侵入性癌症診斷市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • 當前的 COVID-19 市場情景
    • COVID-19後的市場方案或未來情景
  • Covid-19的價格趨勢
  • 需求與供給的頻譜
  • 疫情期間與市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球非侵入性癌症診斷市場-各療法

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析
    • 市場魅力指數
  • 血癌
    • 簡介
    • 市場規模分析(2018-2028),與前一年同期比較成長分析(2020-2028)
  • 肺癌症
  • 乳癌
  • 固態腫瘤
  • 其他

第8章 全球非侵入性癌症診斷市場-各技術

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析
    • 市場魅力指數
  • 臨床化學
    • 簡介
    • 市場規模分析(2018-2028),與前一年同期比較成長分析(2020-2028)
  • 免疫化學/免疫測量
  • 分子診斷
  • 其他

第9章 全球非侵入性癌症診斷市場-各終端用戶

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析
    • 市場魅力指數
  • 醫院
    • 簡介
    • 市場規模分析(2018-2028),與前一年同期比較成長分析(2020-2028)
  • 診所
  • 門診病人手術中心

第10章 全球非侵入性癌症診斷市場-各地區

  • 簡介
    • 市場規模分析(2018-2028),與前一年同期比較成長分析(2020-2028)
    • 市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 主要地區具體動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 主要地區具體動態
    • 各療法:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析

第11章 全球非侵入性癌症診斷市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第12章 全球非侵入性癌症診斷市場-企業簡介概要

  • Roche
    • 企業概要
    • 產品系列·概要
    • 要點
    • 財務概要
  • Precision Therapeutics
  • Affymetrix Inc.
  • Gen-Probe Incorporated
  • AVIVA Biosciences Corporation
  • A&G Pharmaceutical
  • BIOVIEW Inc.
  • Quest Diagnostics Incorporated
  • Digene Corporation
  • Laboratory Corporation of America Holdings
  • LIST NOT EXHAUSTIVE

第13章 全球非侵入性癌症診斷市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global noninvasive cancer diagnostics market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX% during the forecast period (2021-2028).

Noninvasive diagnostics is a method for the detection of disease through minimum incisions into the body. Noninvasive cancer diagnostic technologies give fast and convenient early noninvasive cancer detection procedures, provide a valuable aid to the clinician, and increase comfort. These technologies reduce the mortality rate by providing treatment in the early stage of the disease.

Noninvasive cancer diagnostics is gaining importance over conventional diagnosis due to increased incidences of chronic cancer such as breast cancer and lung cancer.

Market Dynamics

The noninvasive cancer diagnostics market growth is driven by the increasing prevalence of various types of cancer and the growth of the aging population are the major factors driving the growth of the noninvasive cancer diagnostic market.

Increase in incidences of chronic cancer such as breast cancer and lung cancer will drive the market growth

Non-invasive cancer diagnostics is growing importance over conventional diagnosis technique due to increased incidences of chronic cancer such as breast cancer and lung cancer. According to the American Cancer Society, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States in 2020.

Lung cancer still caused more deaths in 2017 than breast, prostate, brain colorectal cancers joined. The mortality drops were also dramatic for melanoma of the skin in the viewing of US Food and Drug Administration approval of novel therapies for metastatic disorder, escalating to 7% annually during 2013 into 2017 from 1% during 2006 by 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in people aged 65 years and older are especially striking because rates in this age group were rising before 2013. It is also renowned that long-term rapid increases in liver cancer death have attenuated women and sustained men. In summary, slowing momentum for some cancers responsive to early detection is compared with notable gains for other common cancers.

Therefore advanced and reliable detection of cancer along with monitoring its growth at later platforms is very critical. Though invasive cancer diagnoses are correct in the early stages, the same procedures cannot be used to monitor cancer tumors at different stages since surgeries are needed for these types of diagnoses. The non-invasive cancer diagnosis market has growth potential all across the world.

The growth of the aging population is the primary factor driving the growth of the noninvasive cancer diagnostic market

As cancer is more prevalent in the elderly population, the rising aging population is also expected to propel market growth. For instance, Global Health and Aging report published by the World Health Organization, the number of people aged 65 years or greater is expected to increase from a predicted 524 million in 2010 to about 1.5 billion by 2050, with a significant percentage of increase in emerging economies. Primary chronic diseases such as cancer have had the most significant impact on the geriatric population, especially in high-income countries.

Detection of cancer at an initial stage significantly raises the possibilities for survival. Creating awareness to promote early diagnosis and screening are the essential steps responsible for early detection of disease comprising breast, blood, colorectal, lung, and cervical, among others. Recognizing likely warning symptoms of cancer and taking active measures is necessary for early diagnosis..

Thus, given the aforementioned factors, the noninvasive cancer diagnostics market is expected to witness tremendous growth over the forecast period.

High expense of diagnostic procedures will hamper the market growth

However, the high expense of diagnostic procedures and stringent regulatory requirements hinder the growth of the global noninvasive cancer diagnostics market..

COVID-19 Impact Analysis

According to the CDC, the senior population with underlying severe therapeutic conditions, including people with cancer, might be at higher risk for severe illness from COVID-19. Patients with cancer are at higher risk for severe COVID-19.

According to a research article by Hidenori Toyoda et al., published in Hepatology Communications Journal 2020, during the COVID-19 pandemic 2020, strict measures were implemented by the government to prevent the spread of COVID-19, which adversely affected the routine monitoring of cancer. Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of cancer products will foster healthy growth of the market amid COVID-19.

Segment Analysis

By therapeutics, the noninvasive cancer diagnostics market is classified into solid tumours, blood cancer, lung cancer, breast cancer, others.

Blood cancer segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

As per the Bristol-Myers Squibb Company report, above 1.85 million new blood cancer cases are anticipated to be diagnosed across the globe in 2040, in which 918,872 cases are from lymphoma, 275,047 cases myeloma and 656,345 from leukemia. Furthermore, the report predicted, in 2040, the estimated number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, higher than 387,000 people lived with leukemia in the U.S., and an expected 68,000 deaths will result from blood cancer. As per the national cancer institute, the expected deaths due to blood cancer are about 22,840 in 2019. The escalating deaths and rising incidence of blood cancer cases globally drive the market.

Based on therapy, the Noninvasive Cancer Diagnostics Market is classified into targeted therapy, radiation therapy, immunotherapy, chemotherapy.

On the basis of techniques, the noninvasive cancer diagnostics market is classified into clinical chemistry, immunochemistry/immunoassay, molecular diagnostics, other clinical instruments.

The molecular diagnostics segment are expected to dominate the noninvasive cancer diagnostics market during the forecast period

Molecular diagnostics recognize the presence of cancer cells by examining their biological molecules. Several tests are conducted on the blood, tumor tissue and saliva, samples for detecting and measuring particular genetic sequences in the RNA, DNA and cell proteins. Molecular diagnostics help perform rapid analysis and provide accurate information that is further used in the personalized diagnosis of cancer. These diagnostics solutions find application in clinical and point-of-care (POC) examinations to detect cancer. They are also utilized in blood banks to identify infectious diseases and pathogens present in the donated blood samples.

Geographical Analysis

North America region holds the largest market share in the global noninvasive cancer diagnostics market

North America region is dominating the global noninvasive cancer diagnostics market accounted for the largest market share in 2020, owing to the growing incidence of cancer cases in the country, the presence of key market players, and the launch of new commodities influence market growth in the region.

As per the American Society of Clinical Oncology 2019 report, an expected 228,150 adults in the United States were expected to be diagnosed with lung cancer. Lung cancer causes up about 13% of all new cancer treatments. Lung cancer is the second common cancer and the foremost cause of cancer death for adults in the US. The report predicted that 142,670 deaths from this disease would occur in the year 2019.

However, North American countries such as the United States and Canada have an advanced and well-structured health care system. These systems also support research and development. These policies support global players to penetrate the US and Canada markets. As a result, these nations enjoy the presence of many market players. As global players in the region meet the high requirement, the market is further expected to increase in the forecast period.

On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.

Competitive Landscape

The noninvasive cancer diagnostics market is moderately competitive with the presence of local as well as global companies. Some of the key players contributing to the growth of the market include Roche, Precision Therapeutics, Affymetrix Inc., Gen-Probe Incorporated, AVIVA Biosciences Corporation, A&G Pharmaceutical, BIOVIEW Inc., Quest Diagnostics Incorporated, Digene Corporation, and Laboratory Corporation of America Holdings. Among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the noninvasive cancer diagnostics market globally.

Roche Diagnostics

Overview: Roche Diagnostics is a diagnostic department of Hoffmann-La Roche, producing equipment and reagents for research and medical diagnostic applications. Applied Science targets research contexts in academia and biotechnology, and pharmaceutical industries. Internally, it is classified into five major business areas: Roche Applied Science, Roche Tissue Diagnostics (Ventana), Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics. The primary location for Roche Professional Diagnostics is in Rotkreuz, Switzerland.

Product Portfolio: The Company's portfolio comprises centralized and point of care solutions, custom biotech, diabetes care, molecular diagnostics & research, among others.

Why Purchase the Report?

  • Visualize the composition of the noninvasive cancer diagnostics market segmentation by therapeutics, techniques, and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in noninvasive cancer diagnostics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of noninvasive cancer diagnostics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global noninvasive cancer diagnostics market report would provide an access to an approx. 61 market data table, 52 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Noninvasive Cancer Diagnostics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Noninvasive Cancer Diagnostics Market - Market Definition and Overview

3. Global Noninvasive Cancer Diagnostics Market - Executive Summary

  • 3.1. Market Snippet by Therapeutics
  • 3.2. Market Snippet by Techniques
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Global Noninvasive Cancer Diagnostics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in incidences of chronic cancer such as breast cancer and lung cancer will drive the market growth
      • 4.1.1.2. The growth of the aging population is the primary factor driving the growth of the noninvasive cancer diagnostic market
    • 4.1.2. Restraints:
      • 4.1.2.1. High expense of diagnostic procedures will hamper the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Noninvasive Cancer Diagnostics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Noninvasive Cancer Diagnostics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Noninvasive Cancer Diagnostics Market - By Therapeutics

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics Segment
    • 7.1.2. Market Attractiveness Index, By Therapeutics Segment
  • 7.2. Blood Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Lung Cancer
  • 7.4. Breast Cancer
  • 7.5. Solid Tumors
  • 7.6. Other

8. Global Noninvasive Cancer Diagnostics Market - By Techniques

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Techniques
    • 8.1.2. Market Attractiveness Index, By Techniques
  • 8.2. Clinical Chemistry*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Immunochemistry/Immunoassay
  • 8.4. Molecular Diagnostics
  • 8.5. Other

9. Global Noninvasive Cancer Diagnostics Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Ambulatory Surgical Centers

10. Global Noninvasive Cancer Diagnostics Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Techniques
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Techniques
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Techniques
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Techniques
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Techniques
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Noninvasive Cancer Diagnostics Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Noninvasive Cancer Diagnostics Market- Company Profiles

  • 12.1. Roche*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Precision Therapeutics
  • 12.3. Affymetrix Inc.
  • 12.4. Gen-Probe Incorporated
  • 12.5. AVIVA Biosciences Corporation
  • 12.6. A&G Pharmaceutical
  • 12.7. BIOVIEW Inc.
  • 12.8. Quest Diagnostics Incorporated
  • 12.9. Digene Corporation
  • 12.10. Laboratory Corporation of America Holdings
  • 12.11. LIST NOT EXHAUSTIVE

13. Global Noninvasive Cancer Diagnostics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us